Stock Ticker

  • Loading stock data...

Delcath Systems, Inc. (NASDAQ:DCTH) Closes In Green

In the last trading session, the stock price of Delcath Systems, Inc. (NASDAQ:DCTH) jumped more than 17% to close the day at $0.122. After the recent gains, the market cap of firm now stands at $60.63 million. More recently, the company congratulated the team at the renowned Medical University of Hannover Hospital on their exception […]

FDA’s Approval For The Study Design By Delcath Systems, Inc (NASDAQ:DCTH) Sparks Excitement Among The Various Concerned Parties

Delcath Systems, Inc (NASDAQ:DCTH) has moved ahead to state that the Food And Drug Administration has given approval to its design of a clinical trial for its Melphalan/HDS drug product and that is of course in line with Special Protocol Assessment. As a matter of fact, A Special Protocol Assessment (SPA) happens to be a […]

Delcath Systems, Inc. (NASDAQ:DCTH) Melphalan / HDS Medicinal Treatment Has Been Accepted For Oral Presentation

It was recently announced that clinical medicine, Melphalan/HDS, which was manufactured by Delcath Systems, Inc. (NADAQ:DCTH) has been accepted for oral presentation. The medicine in question was manufactured, with the specific purpose of treatment for Unresectable Metastatic Ocular Melanoma. This entity is responsible for delivering medical mechanisms, which focus primarily on the treatment of metastatic […]

Delcath Systems, Inc. (NASDAQ:DCTH) Strategic Reorganization

Boston, MA 10/04/2013 (wallstreetpr) – Delcath Systems, Inc. (NASDAQ:DCTH) a leader in pharmaceutical and medical devices has announced plans of how it intends to achieve operation efficiency in the coming years. Part of the reorganization plans involves cutting down on workforce that it does not need. Delcath has completed the reorganization plans by slashing down 21 […]

Sign Up To Get Our Latest Stocks Alerts